Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Erika Puente"'
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
Autor:
Mario Sznol, Adi Diab, Jonathan Zalevsky, Ute Hoch, Mehmet A Bilen, Giovanni Grignani, Nizar M Tannir, Erika Puente, Arjun V Balar, Daniel C Cho, Arlene O Siefker-Radtke, Lily Tang, David Chien, Arkopal Choudhury, Danni Yu, Sue L Currie, Mary A Tagliaferri, Michael E Hurwitz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/b068e058e3794225a3c64c98a9d5c726
Autor:
Mario Sznol, Adi Diab, Brendan Curti, Igor Puzanov, Gregory Daniels, Jonathan Zalevsky, Ute Hoch, Mary Tagliaferri, Michael Hurwitz, Scott Tykodi, Michele Maio, Sekwon Jang, Tuan Nguyen, Wei Lin, Karl Lewis, Alexander Spira, Ewa Kalinka, Daniel Cho, Shanhong Guan, Erika Puente, Sue Currie
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/784e64ffc23649d48d6469271e5284e6
Autor:
Arlene O. Siefker-Radtke, Daniel C. Cho, Adi Diab, Mario Sznol, Mehmet A. Bilen, Arjun V. Balar, Giovanni Grignani, Erika Puente, Lily Tang, David Chien, Ute Hoch, Arkopal Choudhury, Danni Yu, Sue L. Currie, Mary A. Tagliaferri, Jonathan Zalevsky, Michael E. Hurwitz, Nizar M. Tannir
Publikováno v:
European Urology. 82:365-373
Despite recent changes in the treatment landscape, there remains an unmet need for effective, tolerable, chemotherapy-free treatments for patients with advanced/metastatic urothelial carcinoma (mUC), especially cisplatin-ineligible patients.To evalua
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
Autor:
Nizar M Tannir, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen, Arjun V Balar, Giovanni Grignani, Erika Puente, Lily Tang, David Chien, Ute Hoch, Arkopal Choudhury, Danni Yu, Sue L Currie, Mary A Tagliaferri, Jonathan Zalevsky, Arlene O Siefker-Radtke, Michael E Hurwitz
Publikováno v:
Journal for immunotherapy of cancer. 10(4)
BackgroundImmune checkpoint inhibitor-based combinations have expanded the treatment options for patients with renal cell carcinoma (RCC); however, tolerability remains challenging. The aim of this study was to evaluate the safety and efficacy of the
Publikováno v:
Acta neurochirurgica. Supplement. 109
Both awake craniotomy under conscious sedation and use of intraoperative MRI can increase the efficiency and safety of glioma resections. In contrast to craniotomies under general anesthesia, neurosurgery under conscious sedation requires several cha
Autor:
Hassanain, Hamdy H.1 dr.hamdyhassanain@gmail.com, Hassona, Mohamed D. H.2 mohdhessein@yahoo.com, Puente, Erika G.2 Erika.Puente@osumc.edu, Chengwen Sun3 Chengwen.Sun@ndsu.edu, Abouelnaga, Zeinb A.2 Zeinb.Abouelnaga@osumc.edu, Tulman, David B.2 David.Tulman@osumc.edu, Bergese, Sergio D.1,4 Sergio.Bergese@osumc.edu
Publikováno v:
Pharmaceuticals (14248247). May2013, Vol. 6 Issue 5, p623-633. 11p. 1 Chart, 4 Graphs.
Publikováno v:
Women's Health Weekly; 4/15/2024, p1360-1360, 1p
Publikováno v:
Immunotherapy Weekly; 3/14/2023, p715-715, 1p
Publikováno v:
Wilson County News; 12/19/2018, Vol. 45 Issue 51, p8B-8B, 2/3p
Intraoperative MRI (ioMRI) in the Setting of Awake Craniotomies for Supratentorial Glioma Resection.
Publikováno v:
Intraoperative Imaging; 2011, p43-48, 6p